Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.
Lynae Darbes, PhD, presented research on the effectiveness of a home-based intervention for HIV prevention among couples ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback